WO1992007847A1 - Derive de pyrazine fusionnee - Google Patents
Derive de pyrazine fusionnee Download PDFInfo
- Publication number
- WO1992007847A1 WO1992007847A1 PCT/JP1991/001498 JP9101498W WO9207847A1 WO 1992007847 A1 WO1992007847 A1 WO 1992007847A1 JP 9101498 W JP9101498 W JP 9101498W WO 9207847 A1 WO9207847 A1 WO 9207847A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- dione
- imidazolyl
- added
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a fused virazine derivative having glutamate receptor antagonism, particularly NMD A-glycine receptor antagonism and AMPA receptor antagonism, or a salt thereof.
- Amino acids such as L-glutamic acid and L-aspartic acid are known to be transmitters of the central nervous system. When these excitatory amino acids accumulate and excessively stimulate the nerves, hunting ton's chorea, Parkinson's disease, ⁇ ⁇ , senile dementia, cerebral ischemia, and oxygen It is said to lead to neurodegeneration or mental and motor dysfunction observed after deficiency or hypoglycemia.
- drugs capable of regulating the abnormal function of these excitatory amino acids have been considered to be useful in treating trophoblasts and psychiatric disorders.
- L-glutamic acid and L-aspartic acid activate the above receptors and transmit ox-S.
- Excessive amounts of NMDA, AMP A, and kine can affect nerves, causing neuropathy.
- 2-Amino 5-phosphono a selective antagonist of the NMD A receptor Valeric acid or 2-amino-7-phosphonoheptanoic acid has been reported to be effective in experimental animal models of NMDA-induced neuropathy and epilepsy and cerebral ischemia (JP ET, 250, 1 00 (1 989); JPET, 240, 737 (1 9
- the NMDA receptor has been reported to be allosterically fluctuated by the glycine receptor (EJP, 126, 303 (1989)), and is an antagonist of glycine receptors. Has also been reported to be effective in experimental animal models of cerebral ischemia (American Neuroscience Society 1989).
- NBQX 6-ditro 7-sulfamoylpenza [f] quinoxaline
- AP-4 receptor a selective antagonist of the AMP II receptor
- An object of the present invention is to provide a compound having a diketoquinoxaline-based or diketopyridavirazine-based glutamate receptor antagonistic action, particularly an NMDA-glycine receptor and a AMPA receptor antagonistic action. Is what you do. Some diketoquinoxaline derivatives having NMDA monoglycine antagonism and / or AMP A antagonism have been reported (JP-A-63-83074, JP-A-63-258466, JP-A-63-258466).
- the compound of the present invention is imidazolyl as a substituent of a diketoquinoxaline ring or a diketopyridovirazine ring. It is a novel compound that has a chemical structural characteristic in that it has a group or a triazolyl group. That is, the present invention relates to the general formula
- X is a nitrogen atom or an element atom substituted with R 8
- R 6 is a hydrogen atom or a lower alkyl group
- R 7 and R 8 are the same or different, and are a hydrogen atom or a lower alkyl group.
- Nitro group, f: c nil group or both are suspended, buta jenylene group
- R 2 and R 3 are the same or different, Mizusaku atom, fluorine Teruko, Shiano group, I grade Ashiru group, a nitro group, non-S ⁇ is off, lower alkyl group substituted with y atom, a morpholino group, or the meaning of R 1 the same or different 1 and ⁇ one
- R 4 and R 5 are the same or different and each may be substituted with a hydrogen atom, hydrogen, a C110 linear or branched alkyl group or an amino group which may be substituted with C 5-8
- a nitrogen-containing 5- or 6-membered ring which may be S-substituted by a lower alkyl group
- Y represents a hydroxyl group, a lower acyloxy group, a methyl
- R 9 and R 1G are the same or different and are a hydrogen atom, lower alkyl Or a 5- or 6-membered ring group which may contain an oxygen atom when combined with each other).
- the nitrogen-containing 5- or 6-membered heterocyclic group j is, for example, a vinylidyl group, a piperidyl group or the like.
- the heterocyclic group J having a nitrogen-containing 5- or 6-membered heterocyclic group and a cross-linked structure formed by 13 methylene groups is, for example, a quinuclidyl group and the like.
- the ⁇ 5- or 6-membered ring group in which Ft 9 and R 10 may be combined with each other to contain an oxygen atom '' is, for example, a morpholino group or the like.
- the “lower alkyl group” in the definition of the above compound is a linear or branched hydrocarbon chain having 1 to 6 carbon cords. Typical examples are a methyl group, an ethyl group, a butyl group, and an isopropyl group.
- “low carbonyl group J is, for example, a formyl group, an acetyl group, a propionyl group, a butanol group.
- the above compound (I) is a compound having a stereoisomer or tautomer depending on the type of the substituent, and the compound of the present invention includes a separated form or a mixture of these isomers. .
- Examples of the salt of the compound (I) include salts with inorganic acids such as 'hydrochloric acid and hydrobromic acid', and salts with organic acids such as fumaric acid, tartaric acid, alkanesulfonic acid and arylsulfonic acid. And salts with inorganic bases such as sodium hydroxide and potassium hydroxide, and salts with organic bases such as getylamine.
- the compound of the present invention can be produced by the method shown in the following reaction formula.
- Y represents a halogen atom.
- ring A, R, R 2 , RR 7 R 5 , and R 6 have the same meanings as described above.
- a corresponding amount of a halogen compound (II) is reacted with an imidazole or triazole compound (III).
- the reaction is usually dimethylformamide. Dimethylsulfoxide, acetonitrile, acetone, tetrahydrofuran. It is performed by heating in a burble such as. Salts such as sodium hydroxide and sodium hydroxide may be added to promote the reaction.
- the compound of the present invention can be produced by a method represented by the following reaction formula.
- the diamino compound (UY) is reacted with equimolar to transient moles of thiophene or its reaction tk3 ⁇ 4f3 ⁇ 4 (V) at room temperature or under heating.
- Reactions of oxalic acid tkii! ⁇ I include 1 ⁇ 23 ⁇ 4 ⁇ , ⁇ ⁇ ster Si, hydrates, anhydrides, acid chlorides, etc. This reaction is carried out in a normal aqueous or alcoholic solvent. It is preferable to add ⁇ such as 1 ⁇ 2 in order to reduce the reaction.
- This reaction is an isomerization of the low-alkoxalylamino compound (VI), and can be carried out, for example, by a catalytic Liaoyuan method using Raney nickel or the like as a catalyst.
- a catalytic Liaoyuan method using Raney nickel or the like as a catalyst.
- a method there is a method of inserting a new H-substituent into the compound obtained by the above-mentioned production method or converting the substituent.
- R 1 is nitro
- the compound which is a group can be obtained by ditrolation of the corresponding compound which is a purple atom, and the nitration is carried out by converting a compound of the present invention having no dihydroxy group into sulfuric acid or acetic anhydride.
- nitric acid or a salt thereof under acidic or sulfuric acid-acetic anhydride-acetic acid conditions, or heating in an organic solvent such as sulfolane with trifluoromethyl tetrafluoroborate .
- This and also wood Ming compounds performed by What about, NMDA -.
- Effect on glycine receptor and / or AMP Alpha has a strong affinity for receptors NMDA receptor ([3 H] - MK-801 antagonistic activity) was expressed at 1 # ⁇ , and ⁇ receptor binding inhibitory activity was 96% at 1; its K i value was 2 1 eta Micromax. Further, the compound of example 9, 1 5 inhibited audiogenic convulsions 1 5 minutes prior to treatment, at 3 MGK epsilon.
- the compounds of the invention e.g.
- Antagonistic activity and antagonistic activity on NMDA-glycine receptor were determined by a conjugation experiment using [3H] -MK-801 as a ligand.
- the bilateral common carotid artery was occluded for 5 minutes under halothane anesthesia while the rats were kept warm to avoid lowering the body temperature, and the animals were allowed to recover from anesthesia.
- Four days later the brain was excised, a section was prepared, and the degree of neuronal damage in hippocampal CA1 was examined histologically.
- Administration method The compound was dissolved in 0.5% methylcellulose in suspension or saline and administered intraperitoneally. Two administration schedules were performed. In Method 1, 45 minutes, 15 minutes before ischemia, 5 minutes after recanalization, 1 hour, 2 hours, 3 hours fe, 6 hours 24 hours later, a single dose of 30 mg Z kg was administered.
- the compound of the present invention or a salt thereof has a glutamate receptor antagonistic action, particularly an antagonistic action on one or both of NMDA-glycine receptor and AMP A receptor, and in particular, the toxic toxicity of an amino acid having an inhibitory action. It antagonizes the action and also has a jugular activity.
- the compound of the formula (I) or a salt thereof is usually administered systemically or locally, orally or parenterally.
- the dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but it is usually from 1 to 1,000 mg per adult per day, preferably from 50 to 20 mg per day. It is orally administered in divided doses or is intravenously administered once to several times a day in the range of 1 mg to 50 mg per adult per day, or 1 hour to 24 hours. It is administered intravenously for a period of time.
- the dose varies under various conditions, so that a dose smaller than the above range may be sufficient.
- NMR nuclear magnetic resonance spectrum
- MS mass spectrum
- mp melting point
- EA elemental analysis
- 2-Amino 6-imidazolyl 3--3-toropyridine 3.68 g was suspended in a mixed solution of 40 ml of methanol and 2 ml of acetic acid, and 10% palladium-carbon was added. 0.20 g was added and hydrogenated under normal pressure. The reaction solution was filtered, decompressed under reduced pressure, and 24 ml of 4N-hydrochloric acid solution and 1.61 g of oxalic acid were added to the residue, and the mixture was refluxed once. After cooling to room temperature, the resulting crystals were collected and recrystallized from N, N-dimethylformamide to give 6-imidazolylviride [2,3-b] virazine-1,2,3-dione hydrochloride. ⁇ Monohydrate
- the DMSO solution was heated and stirred at 130 for 5.5 hours.
- the reaction solution was poured into ice water, aqueous hydrochloric acid was added, and the insoluble matter was separated at a pH of about 9.
- hydrochloric acid was further added to the solution and the pH was adjusted to about 7, an antagonist crystal precipitated again, and when recovered, 6- (benzimidazol-11yl) -17-nitroquinoxaline-1,2,3- (1H, 4 H) -dione 21 Omg was obtained.
- This antagonist is washed with a small amount of aqueous hydrochloric acid and dried under reduced pressure to give 6-acetyl-7- (1-imidazolyl) quinoxaline-1,2,3- (1H, 4H) dione'hydrochloride. .08 g (23%) of the pentahydrate were obtained.
- reaction solution was allowed to cool, and the generated antagonist was collected, washed with a small amount of aqueous hydrochloric acid, and dried under reduced pressure to give 6- [1- (4-methylthimidazolyl)]-17-tri. 0.28 g (37) of fluoromethylquinoxaline mono 2,3- (1 H, 4 H) dione hydrochloride * dihydrate was obtained.
- 6-Imidazolylquinoxaline-2,3- (1 ⁇ , 4 ⁇ ) Dissolve 0.5 g of monodihydrochloride in 5 ml of sulfuric acid, and add 0.5 g of potassium nitrate. 21 g was added, and the mixture was heated at 70 for 5 minutes. When the temperature returned to room temperature, the mixture was added to ice water, and then the caseisod water was added to PH 4 to 5 to form an antagonist. This was suitable, and re-antagonism with DMF-water yielded 0.27 g of 6-imidazolyl 7- 2-troquinoxaline-1,2,3- (1H, 4H) -dione.
- Physicochemical properties Physicochemical properties:
- Desirable 1 7 (1 imidazoline) 1 6 — 2 to 2 Kinokorin line 2, 3-(1H, 4H) 1 year
- Example 3 4-phenylimidazole was used instead of 2-methylimidazole with -ffl, and 6-2-nitro7- (4-phenylimidazo1-1yl) quinoxaline-1,2,3- (1H, 27Hmg of 4H) -dione 'hydrate was obtained.
- Example 17-14 4-phenylimidazole was used instead of 2-methylimidazole with -ffl, and 6-2-nitro7- (4-phenylimidazo1-1yl) quinoxaline-1,2,3- (1H, 27Hmg of 4H) -dione 'hydrate was obtained.
- Example 17-14 4-phenylimidazole was used instead of 2-methylimidazole with -ffl, and 6-2-nitro7- (4-phenylimidazo1-1yl) quinoxaline-1,2,3- (1H, 27Hmg of 4H) -dione 'hydrate was obtained.
- Example 17-14 4-phenylimidazole was
- Example 17-14-1-1 (2-acetoxityl) -1 7- (1-imidazolyl) 1- (3-ditroquinoxaline-1,2,3- [1H, 4H) -dione
- the mixture was dissolved in m 1 and stirred at 100 ° C. for 3 hours.
- the reaction solution was concentrated, and methanol was added to precipitate crystals.
- 1- (2-hydroxyl) 1 7- (1 imidazolyl) 1-6-2 troquinoxalin 2,3-1 ⁇ , 4 ⁇ ) —dione 'hydrochloride To give 20 Omg.
- Example 17-16 (2-acetoxityl) -1 7- (1-imidazolyl) 1- (3-ditroquinoxaline-1,2,3- [1H, 4H) -dione
- the mixture was dissolved in m 1 and stirred at 100 ° C. for 3 hours.
- the reaction solution was concentrated, and methanol was added to precipitate crystals.
- Example 3 instead of 2-methylimidazole, 41-2 troimidazole was used. Using this, 10 Omg of 6-two-row 7- (412-troimidazo-11-yl) quinoxaline-123-'(1 II, 410 dione) was obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK91918943T DK0556393T3 (da) | 1990-11-06 | 1991-11-01 | Tilkondenseret pyrazinderivat |
| RU93033484/04A RU2095352C1 (ru) | 1990-11-06 | 1991-11-01 | Производное сконденсированного пиразина |
| CA002095444A CA2095444C (en) | 1990-11-06 | 1991-11-01 | Fused pyrazine derivatives |
| HU9301298A HU221425B (en) | 1990-11-06 | 1991-11-01 | Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds |
| AU87666/91A AU656154B2 (en) | 1990-11-06 | 1991-11-01 | Fused pyrazine derivative |
| DE69132340T DE69132340T2 (de) | 1990-11-06 | 1991-11-01 | Kondensiertes pyrazinderivat |
| AT91918943T ATE194985T1 (de) | 1990-11-06 | 1991-11-01 | Kondensiertes pyrazinderivat |
| EP91918943A EP0556393B1 (en) | 1990-11-06 | 1991-11-01 | Fused pyrazine derivative |
| GR20000402315T GR3034629T3 (en) | 1990-11-06 | 2000-10-16 | Fused pyrazine derivative. |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2/300879 | 1990-11-06 | ||
| JP30087990 | 1990-11-06 | ||
| JP3/69592 | 1991-01-11 | ||
| JP6959291 | 1991-01-11 | ||
| JP3/133828 | 1991-03-29 | ||
| JP13382891 | 1991-03-29 | ||
| JP3/183248 | 1991-06-27 | ||
| JP18324891 | 1991-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992007847A1 true WO1992007847A1 (fr) | 1992-05-14 |
Family
ID=27465151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1991/001498 Ceased WO1992007847A1 (fr) | 1990-11-06 | 1991-11-01 | Derive de pyrazine fusionnee |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5283244A (ja) |
| EP (1) | EP0556393B1 (ja) |
| JP (1) | JP2550456B2 (ja) |
| KR (1) | KR0132903B1 (ja) |
| AT (1) | ATE194985T1 (ja) |
| AU (1) | AU656154B2 (ja) |
| CA (1) | CA2095444C (ja) |
| DE (1) | DE69132340T2 (ja) |
| DK (1) | DK0556393T3 (ja) |
| ES (1) | ES2150417T3 (ja) |
| GR (1) | GR3034629T3 (ja) |
| HU (2) | HU221425B (ja) |
| RU (1) | RU2095352C1 (ja) |
| WO (1) | WO1992007847A1 (ja) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022855A1 (en) * | 1993-03-31 | 1994-10-13 | Eisai Co., Ltd. | Nitrogen-containing fused-heterocycle compounds |
| WO1994025469A1 (de) * | 1993-04-28 | 1994-11-10 | Schering Aktiengesellschaft | Neue chinoxalindionderivative, deren herstellung und verwendung in arzneimitteln |
| WO1995018616A3 (en) * | 1994-01-03 | 1995-12-21 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| US5504085A (en) * | 1991-09-20 | 1996-04-02 | Novo Nordisk A/S | Triazolo quinoxalines and their preparation and use |
| US5514680A (en) * | 1992-06-22 | 1996-05-07 | The State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Glycine receptor antagonists and the use thereof |
| US5677305A (en) * | 1994-04-08 | 1997-10-14 | Shionogi & Co., Ltd. | Oxopyridinylquinoxaline derivative |
| US5714489A (en) * | 1992-05-30 | 1998-02-03 | Basf Aktiengesellschaft | 2,3(1H,4H)quinoxalinedione |
| US5773439A (en) * | 1994-06-22 | 1998-06-30 | Basf Aktiengesellschaft | Amido-quinoxalinediones, the preparation and use thereof |
| US5801183A (en) * | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| US5849743A (en) * | 1993-11-24 | 1998-12-15 | Basf Aktiengesellschaft | Quinoxalines and drugs prepared therefrom |
| US5849744A (en) * | 1994-10-14 | 1998-12-15 | Basf Aktiengesellschaft | Pyrrolyl tetrahydrobenzoquinoxaline diones, their preparation and use as glutamate receptor antagonist |
| US5895824A (en) * | 1995-06-09 | 1999-04-20 | Basf Aktiengesellschaft | Preparation of polyether polyols containing aromatics |
| US6057304A (en) * | 1992-10-26 | 2000-05-02 | Schering Aktiengesellschaft | Quinoxaline-phosphonic acid derivatives |
| US6277850B1 (en) | 1996-06-21 | 2001-08-21 | Abbott Laboratories | Pyrrolyl quinoxalindiones their production and use as AMPA receptor antagonists |
| US6703391B2 (en) | 1992-10-13 | 2004-03-09 | Neurosearch A/S | Quinoxalinedione derivatives, their preparation and use |
| US7750028B2 (en) | 1997-06-10 | 2010-07-06 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
| WO2011076946A2 (en) | 2009-12-24 | 2011-06-30 | Universidad Del País Vasco | Methods and compositions for the treatment of alzheimer |
| WO2023042888A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人 琉球大学 | 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物 |
| WO2023042887A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人 琉球大学 | 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| GB9419318D0 (en) * | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
| PL181532B1 (pl) * | 1994-09-27 | 2001-08-31 | Yamanouchi Pharma Co Ltd | Pochodne 1,2,3,4-tetrahydrochinoksalinodionu PL PL PL PL PL PL PL PL PL |
| JP2865878B2 (ja) | 1994-09-27 | 1999-03-08 | 山之内製薬株式会社 | 1,2,3,4−テトラヒドロキノキサリンジオン誘導体 |
| US6110911A (en) * | 1995-06-07 | 2000-08-29 | Warner-Lambert Company | Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| DE19532050A1 (de) * | 1995-08-31 | 1997-03-06 | Basf Ag | Pyrrolyl-tetrahydrochinoxalindione, ihre Herstellung und Verwendung zur Bekämpfung von Krankheiten |
| GB9605027D0 (en) * | 1996-03-09 | 1996-05-08 | Pfizer Ltd | Quinoxalinediones |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| TW448171B (en) * | 1996-06-06 | 2001-08-01 | Yamanouchi Pharma Co Ltd | Imidazole-substituted quinoxalinedione derivatives |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| CN1230889A (zh) | 1996-09-27 | 1999-10-06 | 吉尔福特药业有限公司 | NAALADase组合物和治疗谷氨酸异常及在动物中产生神经元活性的方法 |
| CZ141399A3 (cs) * | 1996-10-24 | 1999-07-14 | Novartis Ag | Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují |
| AP982A (en) * | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
| WO1998038186A1 (en) * | 1997-02-27 | 1998-09-03 | Pfizer Limited | Quinoxalinediones |
| US6015800A (en) * | 1997-09-03 | 2000-01-18 | Warner-Lambert Company | Substituted quinoxaline-2-ones as glutamate receptor antagonists |
| TR200001728T2 (tr) | 1997-11-11 | 2000-09-21 | Ono Pharmaceutical Co., Ltd. | Birleşik pirazin türevleri |
| CN1304404A (zh) * | 1998-06-01 | 2001-07-18 | 盐野义制药株式会社 | 氰基亚氨基喹喔啉衍生物 |
| WO2001055110A1 (en) * | 2000-01-24 | 2001-08-02 | Neurosearch A/S | Isatine derivatives with neurotrophic activity |
| JP4064818B2 (ja) * | 2001-02-12 | 2008-03-19 | エフ.ホフマン−ラ ロシュ アーゲー | 6−置換ピリド−ピリミジン類 |
| CA2612419C (en) * | 2005-06-23 | 2017-06-13 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
| MY148583A (en) * | 2006-04-21 | 2013-04-30 | Pfizer Prod Inc | Pyridine [3,4-b] pyrazinones |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| CA2675419C (en) * | 2007-01-16 | 2013-11-12 | Purdue Pharma L.P. | Heterocyclic-substituted piperidine compounds and the uses thereof |
| WO2008088820A2 (en) | 2007-01-16 | 2008-07-24 | The Johns Hopkins University | Glutamate receptor antagonists and methods of use |
| KR20120102172A (ko) | 2007-08-31 | 2012-09-17 | 시오노기세이야쿠가부시키가이샤 | 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도 |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| WO2022114812A1 (ko) * | 2020-11-26 | 2022-06-02 | 주식회사 엘지화학 | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6383074A (ja) * | 1986-09-16 | 1988-04-13 | ノボ・ノルデイスク・アクツイエルスカブ | キノキサリン化合物並びにその製造法及び用途 |
| JPH01153680A (ja) * | 1987-11-10 | 1989-06-15 | Ferrosan:As | キノキサリン化合物及びその製造と利用 |
| JPH02221263A (ja) * | 1988-12-22 | 1990-09-04 | Ferrosan:As | キノキサリン化合物、その製造方法及びその使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
-
1991
- 1991-11-01 HU HU9301298A patent/HU221425B/hu unknown
- 1991-11-01 CA CA002095444A patent/CA2095444C/en not_active Expired - Fee Related
- 1991-11-01 AU AU87666/91A patent/AU656154B2/en not_active Ceased
- 1991-11-01 DK DK91918943T patent/DK0556393T3/da active
- 1991-11-01 ES ES91918943T patent/ES2150417T3/es not_active Expired - Lifetime
- 1991-11-01 JP JP3517229A patent/JP2550456B2/ja not_active Expired - Fee Related
- 1991-11-01 AT AT91918943T patent/ATE194985T1/de not_active IP Right Cessation
- 1991-11-01 DE DE69132340T patent/DE69132340T2/de not_active Expired - Fee Related
- 1991-11-01 EP EP91918943A patent/EP0556393B1/en not_active Expired - Lifetime
- 1991-11-01 WO PCT/JP1991/001498 patent/WO1992007847A1/ja not_active Ceased
- 1991-11-01 US US08/050,225 patent/US5283244A/en not_active Expired - Lifetime
- 1991-11-01 RU RU93033484/04A patent/RU2095352C1/ru not_active IP Right Cessation
-
1993
- 1993-05-04 KR KR1019930701342A patent/KR0132903B1/ko not_active Expired - Fee Related
-
1995
- 1995-06-30 HU HU95P/P00644P patent/HU211310A9/hu unknown
-
2000
- 2000-10-16 GR GR20000402315T patent/GR3034629T3/el not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6383074A (ja) * | 1986-09-16 | 1988-04-13 | ノボ・ノルデイスク・アクツイエルスカブ | キノキサリン化合物並びにその製造法及び用途 |
| JPH01153680A (ja) * | 1987-11-10 | 1989-06-15 | Ferrosan:As | キノキサリン化合物及びその製造と利用 |
| JPH02221263A (ja) * | 1988-12-22 | 1990-09-04 | Ferrosan:As | キノキサリン化合物、その製造方法及びその使用方法 |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504085A (en) * | 1991-09-20 | 1996-04-02 | Novo Nordisk A/S | Triazolo quinoxalines and their preparation and use |
| US6288065B1 (en) | 1991-10-26 | 2001-09-11 | Schering Aktiengeseellschaft | Quinoxaline-carboxylic acid derivatives |
| US5714489A (en) * | 1992-05-30 | 1998-02-03 | Basf Aktiengesellschaft | 2,3(1H,4H)quinoxalinedione |
| EP0647137A4 (en) * | 1992-06-22 | 1998-09-16 | Univ California Weber Eckard | GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE. |
| US5514680A (en) * | 1992-06-22 | 1996-05-07 | The State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Glycine receptor antagonists and the use thereof |
| US5620979A (en) * | 1992-06-22 | 1997-04-15 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Glycine receptor antagonists and the use thereof |
| US5622952A (en) * | 1992-06-22 | 1997-04-22 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Glycine receptor antagonists and the use thereof |
| US6703391B2 (en) | 1992-10-13 | 2004-03-09 | Neurosearch A/S | Quinoxalinedione derivatives, their preparation and use |
| US6057304A (en) * | 1992-10-26 | 2000-05-02 | Schering Aktiengesellschaft | Quinoxaline-phosphonic acid derivatives |
| WO1994022855A1 (en) * | 1993-03-31 | 1994-10-13 | Eisai Co., Ltd. | Nitrogen-containing fused-heterocycle compounds |
| US5707998A (en) * | 1993-03-31 | 1998-01-13 | Eisai Co., Ltd. | Nitrogen-containing fused-heterocycle compounds |
| US5750525A (en) * | 1993-04-28 | 1998-05-12 | Schering Aktiengesellschaft | Quinoxalinedione derivatives, their production and use in pharmaceutical agents |
| RU2140420C1 (ru) * | 1993-04-28 | 1999-10-27 | Шеринг Аг | Производные хиноксалиндиона, способы их получения, фармацевтическое средство на их основе |
| EP1002796A3 (de) * | 1993-04-28 | 2001-09-12 | Schering Aktiengesellschaft | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| CN1053190C (zh) * | 1993-04-28 | 2000-06-07 | 舍林股份公司 | 新的喹喔啉二酮衍生物、其制备方法和作为药物的应用 |
| WO1994025469A1 (de) * | 1993-04-28 | 1994-11-10 | Schering Aktiengesellschaft | Neue chinoxalindionderivative, deren herstellung und verwendung in arzneimitteln |
| KR100293880B1 (ko) * | 1993-04-28 | 2001-09-17 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | 신규퀴녹살린디온유도체류,그들의제조방법및약제로서의용도 |
| US5955461A (en) * | 1993-04-28 | 1999-09-21 | Schering Aktiengesellschaft | Quinoxalinedione derivatives, their production and use in pharmaceutical agents |
| US5849743A (en) * | 1993-11-24 | 1998-12-15 | Basf Aktiengesellschaft | Quinoxalines and drugs prepared therefrom |
| US5863916A (en) * | 1994-01-03 | 1999-01-26 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher-Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor |
| JP2005247864A (ja) * | 1994-01-03 | 2005-09-15 | Acea Pharmaceuticals Inc | 8−アザ、6−アザ、および6,8−ジアザ−1,4−ジヒドロキノキサリン−2,3−ジオン類 |
| US5620978A (en) * | 1994-01-03 | 1997-04-15 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor |
| WO1995018616A3 (en) * | 1994-01-03 | 1995-12-21 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| US5677305A (en) * | 1994-04-08 | 1997-10-14 | Shionogi & Co., Ltd. | Oxopyridinylquinoxaline derivative |
| US5773439A (en) * | 1994-06-22 | 1998-06-30 | Basf Aktiengesellschaft | Amido-quinoxalinediones, the preparation and use thereof |
| US5849744A (en) * | 1994-10-14 | 1998-12-15 | Basf Aktiengesellschaft | Pyrrolyl tetrahydrobenzoquinoxaline diones, their preparation and use as glutamate receptor antagonist |
| US5801183A (en) * | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| US5895824A (en) * | 1995-06-09 | 1999-04-20 | Basf Aktiengesellschaft | Preparation of polyether polyols containing aromatics |
| US6277850B1 (en) | 1996-06-21 | 2001-08-21 | Abbott Laboratories | Pyrrolyl quinoxalindiones their production and use as AMPA receptor antagonists |
| US7750028B2 (en) | 1997-06-10 | 2010-07-06 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
| WO2011076946A2 (en) | 2009-12-24 | 2011-06-30 | Universidad Del País Vasco | Methods and compositions for the treatment of alzheimer |
| WO2023042888A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人 琉球大学 | 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物 |
| WO2023042887A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人 琉球大学 | 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU656154B2 (en) | 1995-01-27 |
| EP0556393A4 (en) | 1994-04-13 |
| HU9301298D0 (en) | 1993-09-28 |
| HU211310A9 (en) | 1995-11-28 |
| DE69132340D1 (de) | 2000-08-31 |
| HUT64324A (en) | 1993-12-28 |
| RU2095352C1 (ru) | 1997-11-10 |
| HU221425B (en) | 2002-10-28 |
| CA2095444C (en) | 2001-06-19 |
| GR3034629T3 (en) | 2001-01-31 |
| KR0132903B1 (ko) | 1998-04-17 |
| DK0556393T3 (da) | 2000-10-16 |
| EP0556393B1 (en) | 2000-07-26 |
| JP2550456B2 (ja) | 1996-11-06 |
| US5283244A (en) | 1994-02-01 |
| EP0556393A1 (en) | 1993-08-25 |
| CA2095444A1 (en) | 1992-05-07 |
| ES2150417T3 (es) | 2000-12-01 |
| DE69132340T2 (de) | 2001-02-08 |
| AU8766691A (en) | 1992-05-26 |
| ATE194985T1 (de) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1992007847A1 (fr) | Derive de pyrazine fusionnee | |
| JPWO1992007847A1 (ja) | 縮合ピラジン誘導体 | |
| Ohmori et al. | 6-(1H-imidazol-1-yl)-7-nitro-2, 3 (1H, 4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor | |
| CZ290295B6 (cs) | Deriváty chinoxalindionu, způsob jejich výroby a jejich pouľití v léčivech | |
| AU758968B2 (en) | Non-peptide antagonists of GLP-1 receptor and methods of use | |
| JP2740251B2 (ja) | 炭素環式アミド、その製造法、中間体、および該化合物を含有するアレルギー性疾患および炎症性疾患を治療するための製薬学的組成物 | |
| CA1334197C (en) | Hetera-aliphatic carboxamides | |
| WO1993020077A1 (fr) | Derive de quinoxalinone fondue et composition pharmaceutique le contenant | |
| JPH0699430B2 (ja) | 活性化合物,その製造方法及びそれを含む医薬組成物 | |
| CA2146478A1 (en) | Oxopyridinylquinoxaline derivative | |
| JPH02178263A (ja) | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 | |
| US6121265A (en) | Heterocyclic substituted imidazoloquinoxalinones, their preparation and their use | |
| EP0743945A1 (en) | Heterocyclic compounds and their preparation and use | |
| US6121264A (en) | Imidazole-substituted quinoxalinedione derivatives | |
| AU683258B2 (en) | Benzo(F)quinoxalindione derivatives, their preparation and their use in drugs | |
| JP4909889B2 (ja) | 2h−又は3h−ベンゾ[e]インダゾール1−イルカルバメート誘導体、これらの調製及び治療的使用 | |
| US5041460A (en) | Heter-aliphatic carboxamides | |
| JPH07165756A (ja) | ヒドロキシキノキサリンジオン誘導体 | |
| JP4611026B2 (ja) | イミダゾリル化合物の製造のための新規な方法 | |
| JP2889150B2 (ja) | オキソピリジニルキノキサリン誘導体 | |
| US5047402A (en) | Cyclic amides as medicaments | |
| JP2003513959A (ja) | カルボキサミド置換ベンゾイミダゾール誘導体、それらの調製方法及び医薬組成物としてのそれらの使用 | |
| CN114591247A (zh) | 一种替莫唑胺中间体化合物 | |
| JP2003510309A (ja) | 置換ベンゾイミダゾール誘導体、その製造方法及びその医薬組成物としての使用 | |
| JPH08512029A (ja) | イミダゾール誘導体の製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2095444 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991918943 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991918943 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1991918943 Country of ref document: EP |